We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-14.6%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$68.5B
AUM Growth
-$9.16B
(-12%)
Cap. Flow
+$4.06B
Cap. Flow
% of AUM
5.93%
Top 10 Holdings %
Top 10 Hldgs %
21.45%
Holding
3,375
New
359
Increased
2,433
Reduced
285
Closed
282
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$124M |
| 2 |
Apple
AAPL
|
+$110M |
| 3 |
Microsoft
MSFT
|
+$104M |
| 4 |
Amazon
AMZN
|
+$71.3M |
| 5 |
Warner Bros
WBD
|
+$69.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$61.6M |
| 2 |
CERN
Cerner Corp
CERN
|
+$50.9M |
| 3 |
NXP Semiconductors
NXPI
|
+$31.4M |
| 4 |
AZPN
ASPEN TECHNOLOGY INC
AZPN
|
+$30.4M |
| 5 |
Yum China
YUMC
|
+$16.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.13% |
| 2 | Healthcare | 14.42% |
| 3 | Financials | 13.45% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 9.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
Heron Therapeutics
HRTX
$92.9M
| $337K | ﹤0.01% |
120,787
+19,503
| +19% | +$78.3K |
|
2702
Northeast Bank
NBN
$1.14B
| $336K | ﹤0.01% |
+9,191
| New | +$333K |
|
2703
Rocky Brands
RCKY
$369M
| $334K | ﹤0.01% |
9,781
+442
| +5% | +$16.5K |
|
2704
MeiraGTx Holdings
MGTX
$1.21B
| $333K | ﹤0.01% |
43,968
+6,010
| +16% | +$58.3K |
|
|
PVBC
2705
DELISTED
Provident Bancorp
PVBC
| $333K | ﹤0.01% |
21,213
+4,578
| +28% | +$71.3K |
|
2706
RxSight
RXST
$260M
| $333K | ﹤0.01% |
23,665
+11,312
| +92% | +$149K |
|
|
MCBC
2707
DELISTED
Macatawa Bank Corp
MCBC
| $333K | ﹤0.01% |
37,688
+1,628
| +5% | +$14.5K |
|
2708
Edgewise Therapeutics
EWTX
$4.68B
| $332K | ﹤0.01% |
41,714
+4,853
| +13% | +$36.7K |
|
2709
MetLife Inc 4.75% Series F Preferred Stock
MET.PRF
$722M
| $331K | ﹤0.01% |
+14,700
| New | +$330K |
|
2710
Forestar Group
FOR
$1.51B
| $330K | ﹤0.01% |
24,122
+5,237
| +28% | +$82.5K |
|
|
BCOV
2711
DELISTED
Brightcove, Inc.
BCOV
| $330K | ﹤0.01% |
52,154
+10,132
| +24% | +$71.4K |
|
|
CTBB
2712
DELISTED
Qwest Corp 6.5% Notes due 2056
CTBB
| $329K | ﹤0.01% |
+14,300
| New | +$335K |
|
|
DZSI
2713
DELISTED
DZS Inc. Common Stock
DZSI
| $329K | ﹤0.01% |
20,239
+1,704
| +9% | +$25.1K |
|
2714
Oportun Financial
OPRT
$372M
| $328K | ﹤0.01% |
39,638
+13,551
| +52% | +$156K |
|
2715
Sutro Biopharma
STRO
$421M
| $327K | ﹤0.01% |
6,276
+758
| +14% | +$42.3K |
|
2716
Alico
ALCO
$283M
| $326K | ﹤0.01% |
+9,163
| New | +$365K |
|
|
NUVL
2717
DELISTED
Nuvalent
NUVL
| $321K | ﹤0.01% |
23,647
+8,442
| +56% | +$89.3K |
|
|
EIGR
2718
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $321K | ﹤0.01% |
1,701
+430
| +34% | +$86.7K |
|
2719
Goldman Sachs Group Inc Series D Preferred Stock
GS.PRD
$1.02B
| $319K | ﹤0.01% |
+16,800
| New | +$326K |
|
2720
AerSale
ASLE
$279M
| $318K | ﹤0.01% |
21,896
+5,678
| +35% | +$82.4K |
|
2721
Evolv Technologies
EVLV
$1.1B
| $318K | ﹤0.01% |
+119,680
| New | +$318K |
|
2722
Hippo Holdings
HIPO
$861M
| $317K | ﹤0.01% |
14,433
+13,939
| +2,822% | +$515K |
|
2723
Ribbon Communications
RBBN
$383M
| $316K | ﹤0.01% |
103,940
+16,009
| +18% | +$48.4K |
|
|
BBIG
2724
DELISTED
Vinco Ventures, Inc. Common Stock
BBIG
| $316K | ﹤0.01% |
+11,454
| New | +$384K |
|
2725
Information Services Group
III
$248M
| $315K | ﹤0.01% |
+46,614
| New | +$293K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, RhumbLine Advisers held 3,375 positions worth $68.5B, down 12% from $77.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
RhumbLine Advisers deployed $4.06B of net new capital in Q2 2022, opening 359 new positions and adding to 2,433 existing holdings. Its largest new stake was Aspen Technology Inc: 81,883 shares worth $15M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was AT&T, an estimated $61.6M trimmed.
- RhumbLine Advisers's largest Q2 2022 buy was Aspen Technology Inc: 81,883 shares worth $15M.
- RhumbLine Advisers added most to Linde in Q2 2022, an estimated $124M increase.
- RhumbLine Advisers's biggest Q2 2022 reduction was AT&T, cutting an estimated $61.6M.
- RhumbLine Advisers fully exited Cerner Corp in Q2 2022, selling an estimated $50.9M.
- RhumbLine Advisers's ten largest holdings make up 21% of its $68.5B portfolio in Q2 2022.
- RhumbLine Advisers opened 359 new positions and closed 282 in Q2 2022.
- RhumbLine Advisers's portfolio value fell 12% quarter-over-quarter to $68.5B.
Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.